Payment overview · 2025
General Payments
$193.60
11 reported records · 10 companies
Healthcare provider profile · identity verified
Megan E Ashbacher, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DEFIANCE, OH · NPI 1124544614
Verified facts
What the public records show
CMS Open Payments records show Megan E Ashbacher, CNP received $193.60 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.07 | 16.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.65 | 12.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.19 | 10.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.89 | 10.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.06 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.23 | 8.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.63 | 8.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.30 | 8.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.89 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.69 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.60 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.07 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 196 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 147 | 43 |
| Omeprazole | Omeprazole | 146 | 55 |
| Lisinopril | Lisinopril | 138 | 53 |
| Prednisone | Prednisone | 129 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 42 |
| Losartan Potassium | Losartan Potassium | 71 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 68 | 30 |
| Gabapentin | Gabapentin | 66 | 21 |
| Furosemide | Furosemide | 65 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 25 |
| Cephalexin | Cephalexin | 61 | 57 |
| Eliquis | Apixaban | 61 | 15 |
| Tramadol Hcl | Tramadol Hcl | 61 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Simvastatin | Simvastatin | 56 | 22 |
| Buspirone Hcl | Buspirone Hcl | 54 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 47 | 21 |
| Alprazolam | Alprazolam | 46 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 18 |
| Meloxicam | Meloxicam | 45 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 41 |
| Metformin Hcl Er | Metformin Hcl | 43 | 17 |
| Sertraline Hcl | Sertraline Hcl | 43 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 15 |
| Carvedilol | Carvedilol | 37 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 13 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 15 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Famotidine | Famotidine | 28 | 14 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 11 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Lorazepam | Lorazepam | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.60 · 11 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, General - Pain Management, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, XIFAXAN, ZAVZPRET, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error